m360 Research

Drug development is built on decisions. ➡️ Which therapeutic area should we invest in? ➡️ How differentiated is our asset? ➡️ Which competitors matter most? ➡️ When is the right time to enter the market?  The answers rarely come from a single source. Clinical trials, scientific publications, regulatory decisions, conference presentations and competitor announcements each provide part of the picture. The challenge is interpreting how those developments fit together and what they mean for future strategy. Continue reading: https://hubs.ly/Q04q_Dlh0 #CompetitiveIntelligence #Pharma #ValueChain

Every stage of the pharmaceutical value chain raises different strategic questions. ✅ Early development focuses on opportunity ✅ Clinical development focuses on competitor evidence ✅ Regulatory review focuses on approvals and market access ✅ Commercial teams focus on positioning, competitor activity and market evolution Our Competitive Intelligence team supports life sciences organisations across the pharmaceutical value chain through tailored programmes, from therapy area landscape assessments and conference coverage to long-term competitor monitoring. Learn more about our Competitive Intelligence capabilities: https://hubs.ly/Q04pBRVv0 #CompetitiveIntelligence #LifeSciences #Pharma

Through m360 Research and the wider M3 network, we support oncology recruitment across the US with nationwide coverage and access to specialised audiences across multiple oncology disciplines. Learn more: https://hubs.ly/Q04kN4_10 #OncologyResearch #HealthcareMarketResearch #Fieldwork

Recruiting oncologists for healthcare research in the US is becoming more complex.   Research teams increasingly need clinicians with experience across specific tumour types, treatment pathways and emerging therapies, not just broad specialty representation.  Many studies also require a mix of participants from:  ✅ academic cancer centres  ✅ integrated delivery networks  ✅ community oncology practices  Teams often need to balance those recruitment requirements alongside regional quotas, niche incidence rates and fieldwork timelines.  As oncology pipelines become more specialised, recruiters and healthcare research teams are having to work harder to identify the right clinicians at the right speed.  What is creating the biggest challenge in oncology recruitment today: incidence, timelines, geographic coverage or specialist qualification?  #OncologyResearch #HealthcareMarketResearch #HealthcareInsights 

Since Q3 2024, our US specialist recruitment network has grown by more than 46%, expanding access across oncology subspecialties, treatment settings and clinical research hubs throughout the US.  If you are recruiting oncologists or related specialists for upcoming research, partner with m360 Research to support your next project.  View our oncology recruitment overview here: https://hubs.ly/Q04kNLHB0 #HealthcareMarketResearch #Fieldwork #Oncology

We help life sciences teams monitor competitors, interpret key developments and act with greater clarity across the product lifecycle. Speak to an expert today: https://hubs.ly/Q04jzQgj0 #m360Research #CompetitiveIntelligence #Pharma

Competitive intelligence should do more than track activity. It should help teams understand what matters and make better decisions. At m360 Research, we support this through three core areas. Each designed to bring clarity to complex and evolving competitive landscapes. To explore how we can support your team, visit our landing page: https://hubs.ly/Q04kS1zV0 #CompetitiveIntelligence #LifeSciences #HealthcareInsights

Through m360 Research and the wider M3 network, we support oncology recruitment across the US with access to clinicians across major clinical and research hubs including California, New York, Texas, Florida, Pennsylvania and Massachusetts. These markets include academic cancer centres, integrated delivery networks, community oncology practices and regions with high clinical trial activity. We also support recruitment across smaller and mid-sized states, helping healthcare research teams reduce recruitment bottlenecks, balance regional quotas and strengthen nationwide market representation. #OncologyResearch #HealthcareMarketResearch #Fieldwork

As oncology research becomes more specialised, healthcare research teams face a more difficult recruitment environment. Tumour-specific expertise, evolving treatment pathways and rapid advances in targeted therapies have made it harder to identify and engage the right clinicians for research. Through m360 Research and the wider M3 network, we support recruitment across oncology subspecialties throughout the US, helping teams reach both academic and community-based clinicians across a broad range of oncology subspecialties. Our teams support recruitment across: ✅ Solid and haematologic malignancies ✅ Community and academic oncology settings ✅ Rare and difficult-to-reach specialties ✅ Emerging therapy areas and evolving standards of care View our oncology recruitment overview and find out how we can support your next project: https://hubs.ly/Q04hsKqT0 #OncologyResearch #HealthcareMarketResearch #Fieldwork

It’s time to celebrate the m360 Research Q1 Leaders Awards! 🏆 Congratulations to our leader winner, Subir Gadia, and our leader runner-up, R Mohammed Ajmal Khan Your leadership, commitment and impact throughout the quarter have truly stood out. This recognition is incredibly well-deserved, and we’re proud to have you leading the way at m360 Research. #m360Research #MarketResearch #Healthcare